Sanofi SA has announced its agreement to purchase Dynavax Technologies Corporation for $15.50 per share in cash, totaling about $2.2 billion. This acquisition will enhance Sanofi's position in adult immunization. One key asset is Dynavax's adult hepatitis B vaccine HEPLISAV-B, available in the U.S., known for its two-dose regimen that provides faster seroprotection compared to other vaccines requiring three doses over six months. The transaction also encompasses Dynavax's shingles vaccine candidate. This strategic move aims to bolster Sanofi's vaccine portfolio.